

side effects, difficulty identifying appropriate healthcare providers, etc.)

- What specific things would you look for in an ideal treatment for your condition? For example, which symptom would you most like a treatment to target and what would you consider to be a meaningful improvement in this symptom?

The scientific workshop on October 28, 2014 will include a discussion of scientific challenges related to:

- Diagnosis of the condition for clinical trials and in clinical practice and
- ensuring valid patient-reported outcome measures for the key efficacy endpoints used in clinical trials.

B. Meeting and Workshop Attendance and Participation

If you wish to attend the Patient-Focused Drug Development meeting or scientific workshop, visit <http://fsdpatientfocused.eventbrite.com>.

Please register for either the meeting or workshop by October 17, 2014. If you are unable to attend the meeting or workshop in person, you can register to view a live Webcast. You will be asked to indicate in your registration whether you plan to attend in person or via the Webcast.

Seating will be limited, so early registration is recommended. Registration is free and will be on a first-come, first-served basis. However, FDA may limit the number of participants from each organization based on space limitations. Registrants will receive confirmation once they have been accepted. Onsite registration on the day of the meetings will be based on space availability. If you need special accommodations because of disability, please contact Pujita Vaidya or Charlene Williamson (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days before the meeting.

Patients who are interested in presenting comments as part of the initial panel discussions during the October 27 meeting must indicate in their registration which topic(s) they wish to address. These patients also must send a brief summary of responses to the topic questions by October 3, 2014, to PatientFocused@fda.hhs.gov. Panelists will be notified of their selection approximately 7 days before the public meeting. We will try to accommodate all patients and patient stakeholders who wish to speak, either through the panel discussion or audience participation; however, the duration of comments may be limited by time constraints.

FDA will hold an open public comment period during the October 27

meeting and the October 28 workshop to give the public an opportunity to comment. Registration for open public comment will occur at the registration desk on the day of the meeting and workshop on a first-come, first-serve basis.

III. Comments

Regardless of attendance at the Patient-Focused Drug Development meeting, you can submit electronic or written comments, including responses to the questions pertaining to Topics 1 and 2, to the public docket (see **ADDRESSES**) by December 29, 2014.

Please indicate whether the comments are relevant to the October 27 meeting or the October 28 workshop. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at <http://www.regulations.gov>.

IV. Transcripts

As soon as a transcript is available, FDA will post it at <http://www.fda.gov/Drugs/NewsEvents/ucm401167.htm>.

Dated: September 23, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2014-22983 Filed 9-25-14; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

National Vaccine Injury Compensation Program; List of Petitions Received

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Health Resources and Services Administration (HRSA) is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by Section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of Health and Human Services is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for filing petitions, and the Program in general, contact the Clerk, United States

Court of Federal Claims, 717 Madison Place NW., Washington, DC 20005, (202) 357-6400. For information on HRSA's role in the Program, contact the Director, National Vaccine Injury Compensation Program, 5600 Fishers Lane, Room 11C-26, Rockville, MD 20857; (301) 443-6593.

SUPPLEMENTARY INFORMATION: The Program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 300aa-10 *et seq.*, provides that those seeking compensation are to file a petition with the U.S. Court of Federal Claims and to serve a copy of the petition on the Secretary of Health and Human Services, who is named as the respondent in each proceeding. The Secretary has delegated this responsibility under the Program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the Table) set forth at Section 2114 of the PHS Act or as set forth at 42 CFR 100.3, as applicable. This Table lists for each covered childhood vaccine the conditions which may lead to compensation and, for each condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested outside the time periods specified in the Table, but only if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2), requires that "[w]ithin 30 days after the Secretary receives service of any petition filed under section 2111 the Secretary shall publish notice of such petition in the **Federal Register**." Set forth below is a list of petitions received by HRSA on August 1, 2014, through August 31, 2014. This list provides the name of petitioner, city and state of vaccination (if unknown then city and state of person or attorney filing claim), and case number. In cases where the Court has redacted the name of a petitioner and/or the case number, the list reflects such redaction.

Section 2112(b)(2) also provides that the special master “shall afford all interested persons an opportunity to submit relevant, written information” relating to the following:

1. The existence of evidence “that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition,” and
2. Any allegation in a petition that the petitioner either:
 - (a) “Sustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Vaccine Injury Table but which was caused by” one of the vaccines referred to in the Table, or
 - (b) “Sustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine” referred to in the Table.

In accordance with Section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the U.S. Court of Federal Claims at the address listed above (under the heading “For Further Information Contact”), with a copy to HRSA addressed to Director, Division of Injury Compensation Programs, Healthcare Systems Bureau, 5600 Fishers Lane, Room 11C-26, Rockville, MD 20857. The Court’s caption (Petitioner’s Name v. Secretary of Health and Human Services) and the docket number assigned to the petition should be used as the caption for the written submission. Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program.

Dated: September 19, 2014.

Mary K. Wakefield,
Administrator.

List of Petitions Filed

1. Patricia Trujillo, Espanola, New Mexico, Court of Federal Claims No: 14-0692V
2. Rebecca Russell, Birmingham, Alabama, Court of Federal Claims No: 14-0693V
3. Michael Phillips, Alpena, Michigan, Court of Federal Claims No: 14-0694V
4. Mark Lattimore, Oro Valley, Arizona, Court of Federal Claims No: 14-0695V
5. Mary Schoeberlein, Baltimore, Maryland, Court of Federal Claims No: 14-0697V
6. Lisa Otto on behalf of A.O., Dallas, Texas, Court of Federal Claims No: 14-0698V
7. Jamileh Berenji and Bahman Yousefi on behalf of S.Y., Sunnyvale, California, Court of Federal Claims No: 14-0699V
8. Mariana Glenn Anderson, Anderson, South Carolina, Court of Federal Claims No: 14-0700V
9. Susan Sudman, Edgewater, Maryland, Court of Federal Claims No: 14-0701V
10. Susan Lee, Olney, Maryland, Court of Federal Claims No: 14-0702V
11. Kathleen Wyatt, Beachwood, Ohio, Court of Federal Claims No: 14-0706V
12. Amy L. Rawson on behalf of Michaela Renee Rawson, Somers Point, New Jersey, Court of Federal Claims No: 14-0707V
13. Melody Hawkins on behalf of Timberly Hawkins, Crossett, Arkansas, Court of Federal Claims No: 14-0708V
14. Chad McClellan on behalf of L.M., Herriman, Utah, Court of Federal Claims No: 14-0714V
15. Charles Thomas on behalf of Cheryll Thomas, Deceased, New Hyde Park, New York, Court of Federal Claims No: 14-0715V
16. Carol Lynch, Greensboro, Georgia, Court of Federal Claims No: 14-0716V
17. Robyn Chang on behalf of E.F., Opelika, Alabama, Court of Federal Claims No: 14-0717V
18. Nelson Stanley Cummings, Bridgton, Maine, Court of Federal Claims No: 14-0721V
19. Jorge Rodriguez on behalf of Marlenny Rodriguez, Elmhurst, New York, Court of Federal Claims No: 14-0722V
20. Sara Erickson, Hamilton, New Jersey, Court of Federal Claims No: 14-0724V
21. Karen Sullivan, Calhoun, Georgia, Court of Federal Claims No: 14-0725V
22. Trent Kuzman on behalf of Inea Kuzman, Carlsbad, California, Court of Federal Claims No: 14-0726V
23. Michael Schlaak on behalf of J.N.S., Appleton, Wisconsin, Court of Federal Claims No: 14-0727V
24. Lynn Martin, Manhasset, New York, Court of Federal Claims No: 14-0730V
25. Pansy Downs, Hickory, North Carolina, Court of Federal Claims No: 14-0731V
26. Franklin Jenkins, Boston, Massachusetts, Court of Federal Claims No: 14-0732V
27. Fredrick Richardson, Springfield, Ohio, Court of Federal Claims No: 14-0733V
28. Melissa Hall, Wood River, Nebraska, Court of Federal Claims No: 14-0734V
29. Michael O’Leary, Philadelphia, Pennsylvania, Court of Federal Claims No: 14-0737V
30. Clementine Block, Berkeley Heights, New Jersey, Court of Federal Claims No: 14-0739V
31. Sara Elizabeth Sajbel on behalf of B.B.T., Deceased, Pueblo, Colorado, Court of Federal Claims No: 14-0741V
32. Jasmine Dark, Houston, Texas, Court of Federal Claims No: 14-0742V
33. Nancy Riggs, Parkersburg, West Virginia, Court of Federal Claims No: 14-0743V
34. Kathleen Farina, Maywood, Illinois, Court of Federal Claims No: 14-0745V
35. Cory Danielson, Colorado Springs, Colorado, Court of Federal Claims No: 14-0746V
36. Nicole Solomon, Avon, Indiana, Court of Federal Claims No: 14-0748V
37. Susan Charbonneau, Milwaukie, Oregon, Court of Federal Claims No: 14-0749V
38. Panagoula E. Bekiaris, Park Ridge, Illinois, Court of Federal Claims No: 14-0750V
39. Melissa Walter, Lakeland, Florida, Court of Federal Claims No: 14-0751V
40. Stanley Brass, Plantation, Florida, Court of Federal Claims No: 14-0752V
41. Elizabeth Manning, Waukesha, Wisconsin, Court of Federal Claims No: 14-0753V
42. Keith Snow on behalf of R.S., Marlborough, Connecticut, Court of Federal Claims No: 14-0754V
43. Daniel Werner, Superior, Colorado, Court of Federal Claims No: 14-0755V
44. Kristina Garrison, Buhl, Idaho, Court of Federal Claims No: 14-0762V
45. Amanda Callahan on behalf of J.B., Decatur, Indiana, Court of Federal Claims No: 14-0763V
46. Michelle Brittain on behalf of S.Y., Dallas, Texas, Court of Federal Claims No: 14-0764V
47. Donald Jones-Fogle, Waynesboro, Pennsylvania, Court of Federal Claims No: 14-0765V

48. Joan Rosof, Lafayette, Colorado, Court of Federal Claims No: 14–0766V
49. Jennifer Ratterman, Newport, Kentucky, Court of Federal Claims No: 14–0767V
50. Patty Ferraro on behalf of A.F., Venice, Florida, Court of Federal Claims No: 14–0770V
51. Kenneth Shores, Grants Pass, Oregon, Court of Federal Claims No: 14–0771V
52. Timothy Steinruck on behalf of E.J.S., Deceased, Amherst, New Hampshire, Court of Federal Claims No: 14–0772V
53. Genice Jarman, Naples, Florida, Court of Federal Claims No: 14–0773V
54. Wiley Terry, Sarasota, Florida, Court of Federal Claims No: 14–0774V
55. Jill Buchignani-Calwhite, Tampa, Florida, Court of Federal Claims No: 14–0775V
56. Jamie Rothstein, Philadelphia, Pennsylvania, Court of Federal Claims No: 14–0778V
57. Jaswinder Singh, Carlsbad, California, Court of Federal Claims No: 14–0779V
58. Richard J. Michel, Phillipsburg, New Jersey, Court of Federal Claims No: 14–0781V
59. Kristin Lintz, Bloomington, Indiana, Court of Federal Claims No: 14–0784V
60. Cynthia Hamilton and Robert Hamilton on behalf of R.M.H., New York, New York, Court of Federal Claims No: 14–0785V
61. Cheryl Simmons, Wilmington, Delaware, Court of Federal Claims No: 14–0788V
62. Michelene Falsini, Salem, New Hampshire, Court of Federal Claims No: 14–0789V
63. Michael McCollum, Seaside, California, Court of Federal Claims No: 14–0790V
64. Linda Heeg, Marshfield, Wisconsin, Court of Federal Claims No: 14–0795V
65. Jacqueline Freeman, Lexington, North Carolina, Court of Federal Claims No: 14–0796V

[FR Doc. 2014–23026 Filed 9–25–14; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; R13 Conference Grant Review.

Date: October 30, 2014.

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W556, Rockville, MD 20850, (Telephone Conference Call).

Contact Person: Bratin K. Saha, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W556, Rockville, MD 20850, 240–276–6411, sahab@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Omnibus SEP–1.

Date: November 4–5, 2014.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Zhiqiang Zou, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, 9609 Medical Center Drive, Room 7W242, Bethesda, MD 20892–9750, 240–276–6372, zouzhiq@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; Training and Career Development Application Review.

Date: December 3, 2014.

Time: 2:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W110, Rockville, MD 20850, (Telephone Conference Call).

Contact Person: Robert Bird, Ph.D., Chief, Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, 7W110, Bethesda, MD 20892, 240–276–6344, birdr@mail.nih.gov.

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/sep/sep.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: September 22, 2014.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–22892 Filed 9–25–14; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Patient-Oriented Research Review Committee.

Date: October 22–23, 2014.

Time: 8:30 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

Contact Person: Stephanie Johnson Webb, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7196, Bethesda, MD 20892, 301–435–0291, stephanie.webb@nih.gov.

Name of Committee: Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Clinical and Basic Science Review Committee.

Date: October 23–24, 2014.

Time: 10:30 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Crystal City, Arlington, VA 22202.

Contact Person: Keith A. Mintzer, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room